<DOC>
	<DOCNO>NCT02004704</DOCNO>
	<brief_summary>The primary objective study obtain data regard safety olipudase alfa patient acid sphingomyelinase deficiency ( ASMD ) expose long term treatment olipudase alfa . The secondary objective study obtain data regard efficacy olipudase alfa characterize olipudase alfa pharmacodynamics ( PD ) pharmacokinetics ( PK ) follow long-term administration .</brief_summary>
	<brief_title>A Long-Term Study Olipudase Alfa Patients With Acid Sphingomyelinase Deficiency</brief_title>
	<detailed_description>5 year : This study extension study patient complete previous study olipudase alfa ( DFI13803 pediatric patient , DFI13412 adult patient ) .</detailed_description>
	<mesh_term>Niemann-Pick Disease , Type A</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type C</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<criteria>Inclusion criterion : The patient complete treatment period previous study olipudase alfa acceptable safety profile opinion investigator sponsor . The patient and/or patient 's parent ( ) /legal guardian ( ) willing able provide sign write informed consent . The patient female childbearing potential must negative urine pregnancy test beta human chorionic gonadotropin ( Î² HCG ) . Female patient childbearing potential sexually mature male patient must willing practice true abstinence line prefer usual lifestyle use 2 acceptable effective method contraception 15 day follow last dose study drug Exclusion criterion : The patient new condition worsen exist condition opinion investigator would make patient unsuitable enrollment , could interfere patient participate complete study . The patient , opinion investigator , unable adhere requirement study . The patient unwilling unable abstain use alcohol 1 day prior 3 day olipudase alfa infusion duration treatment period . The patient unwilling unable avoid , 10 day 3 day liver biopsy , medication herbal supplement potentially hepatotoxic ( eg , 3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor , erythromycin , valproic acid , antidepressant , kava , echinacea ) may cause prolong bleeding ( eg , anticoagulant , ibuprofen , aspirin , garlic supplement , ginkgo , ginseng ) . The patient require medication ( ) may decrease olipudase alfa activity ( eg , fluoxetine , chlorpromazine ; tricyclic antidepressant [ eg , imipramine , desipramine ] ) . The patient alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 250 IU/L total bilirubin &gt; 1.5 mg/dL . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>